Skip to main content
. 2023 Apr 3;17(4):915–926. doi: 10.1007/s12072-023-10519-8

Fig. 2.

Fig. 2

Kaplan–Meier curves of overall survival (a) and progression-free survival (b) in two groups before propensity score matching. TACE transcatheter arterial chemoembolization, A apatinib, C camrelizumab. Data were presented as median (95% confidence interval). Two groups were compared using log-rank test